Filtered By:
Specialty: Biomedical Science
This page shows you your search results in order of date. This is page number 10.
Order by Relevance | Date
Total 5325 results found since Jan 2013.
Clinical Characteristics and Risk Factors for Mortality in Critical COVID-19 Patients Aged 50 Years or Younger During Omicron Wave in Korea: Comparison With Patients Older Than 50 Years of Age
CONCLUSION: Overall, the S-CFR of critically ill COVID-19 patients in the omicron period was higher than that in the delta period, especially in those aged ≤ 50 years. All of the patients who died had an underlying disease or obesity. In the same population, the vaccination rate was very low compared to that in the delta wave, indicating that non-vaccination significantly affected the progression to critical illness. Notably, there was a lack of prescription for Paxlovid for these patients although they satisfied the prescription criteria. Early diagnosis and active initial treatment was necessary, along with the proven ...
Source: Journal of Korean Medical Science - July 18, 2023 Category: Biomedical Science Authors: Hye Jin Shi Jinyoung Yang Joong Sik Eom Jae-Hoon Ko Kyong Ran Peck Uh Jin Kim Sook In Jung Seulki Kim Hyeri Seok Miri Hyun Hyun Ah Kim Bomi Kim Eun-Jeong Joo Hae Suk Cheong Cheon Hoo Jun Yu Mi Wi Jungok Kim Sungmin Kym Seungjin Lim Yoonseon Park Source Type: research
A longitudinal investigation of the effects of the COVID-19 pandemic on 2SLGBTQ+ youth experiencing homelessness
ConclusionStudy results showed high rates of mental health issues among 2SLGBTQ+ youth, but reduced access to mental health care, due to the COVID-19 pandemic. Findings highlight the need for 2SLGBTQ+ inclusive and affirming mental health care and services to address social and mental health issues that have been exacerbated by the pandemic.
Source: PLoS One - July 17, 2023 Category: Biomedical Science Authors: Alex Abramovich Source Type: research
Kinetics of specific anti-SARS-CoV-2 IgM, IgA, and IgG responses during the first 12 months after SARS-CoV-2 infection: A prospective longitudinal study
We present the first study in Africa to measure the kinetics of antibody response (IgA, IgM and IgG) to SARS-CoV-2 over one year. Most participants remained seropositive for anti-RBD IgG after one year but showed a significant decline in antibody titers.
Source: PLoS One - July 12, 2023 Category: Biomedical Science Authors: Houda Amellal Source Type: research
Risk Factors for Sudden Death Within 2 Days After Diagnosis of COVID-19 in Korea
CONCLUSION: To our knowledge, this is the first study on the risk factors for sudden death after a diagnosis of COVID-19, which included age, underlying condition, vaccination status, and place of death. Additionally, individuals aged < 60 years without an underlying condition were at high risk for sudden death. However, this group has relatively low interest in health, as can be seen from the high non-vaccination rate (16.1% of the general population vs. 61.6% of the corresponding group). Therefore, there is a possibility for the presence of an uncontrolled underlying disease in this population. In addition, many sudde...
Source: Journal of Korean Medical Science - July 11, 2023 Category: Biomedical Science Authors: So Young Choi Boyeong Ryu Hyun-Ju Lee Dong-Hwii Kim Eunjeong Shin Seong-Sun Kim Donghyok Kwon Source Type: research
Effectiveness of Paxlovid, an Oral Antiviral Drug, Against the Omicron BA.5 Variant in Korea: Severe Progression and Death Between July and November 2022
CONCLUSION: Paxlovid is effective at reducing the risk of death due to COVID-19 in patients with omicron BA.5 infection, especially in older patients, regardless of vaccination status. This suggests that older patients with COVID-19-related symptoms should be administered Paxlovid, regardless of their vaccination status, to reduce severity and risk of death.PMID:37431541 | PMC:PMC10332951 | DOI:10.3346/jkms.2023.38.e211
Source: Journal of Korean Medical Science - July 11, 2023 Category: Biomedical Science Authors: Jong Mu Kim Min-Gyu Yoo Soon Jong Bae Jungyeon Kim Hyungmin Lee Source Type: research
Loss of Neutralizing Activity of Tixagevimab/Cilgavimab (Evusheld ™) Against Omicron BN.1, a Dominant Circulating Strain Following BA.5 During the Seventh Domestic Outbreak in Korea in Early 2023
J Korean Med Sci. 2023 Jul 10;38(27):e205. doi: 10.3346/jkms.2023.38.e205.ABSTRACTTixagevimab/cilgavimab is a monoclonal antibody used to prevent coronavirus disease 2019 among immunocompromised hosts and maintained neutralizing activity against early omicron variants. Omicron BN.1 became a dominant circulating strain in Korea early 2023, but its susceptibility to tixagevimab/cilgavimab is unclear. We conducted plaque reduction neutralization test (PRNT) against BN.1 in a prospective cohort (14 patients and 30 specimens). BN.1 PRNT was conducted for one- and three-months after tixagevimab/cilgavimab administration and the ...
Source: Journal of Korean Medical Science - July 11, 2023 Category: Biomedical Science Authors: Jinyoung Yang Seokhwan Hyeon Jin Yang Baek Min Seo Kang Keon Young Lee Young Ho Lee Kyungmin Huh Sun Young Cho Cheol-In Kang Doo Ryeon Chung Kyong Ran Peck Gunho Won Hye Won Lee Kwangwook Kim Insu Hwang So Yeon Lee Byung Chul Kim Yoo-Kyoung Lee Jae-Hoon K Source Type: research
Risk Factors for Sudden Death Within 2 Days After Diagnosis of COVID-19 in Korea
CONCLUSION: To our knowledge, this is the first study on the risk factors for sudden death after a diagnosis of COVID-19, which included age, underlying condition, vaccination status, and place of death. Additionally, individuals aged < 60 years without an underlying condition were at high risk for sudden death. However, this group has relatively low interest in health, as can be seen from the high non-vaccination rate (16.1% of the general population vs. 61.6% of the corresponding group). Therefore, there is a possibility for the presence of an uncontrolled underlying disease in this population. In addition, many sudde...
Source: Journal of Korean Medical Science - July 11, 2023 Category: Biomedical Science Authors: So Young Choi Boyeong Ryu Hyun-Ju Lee Dong-Hwii Kim Eunjeong Shin Seong-Sun Kim Donghyok Kwon Source Type: research
Effectiveness of Paxlovid, an Oral Antiviral Drug, Against the Omicron BA.5 Variant in Korea: Severe Progression and Death Between July and November 2022
CONCLUSION: Paxlovid is effective at reducing the risk of death due to COVID-19 in patients with omicron BA.5 infection, especially in older patients, regardless of vaccination status. This suggests that older patients with COVID-19-related symptoms should be administered Paxlovid, regardless of their vaccination status, to reduce severity and risk of death.PMID:37431541 | DOI:10.3346/jkms.2023.38.e211
Source: Journal of Korean Medical Science - July 11, 2023 Category: Biomedical Science Authors: Jong Mu Kim Min-Gyu Yoo Soon Jong Bae Jungyeon Kim Hyungmin Lee Source Type: research
Loss of Neutralizing Activity of Tixagevimab/Cilgavimab (Evusheld ™) Against Omicron BN.1, a Dominant Circulating Strain Following BA.5 During the Seventh Domestic Outbreak in Korea in Early 2023
J Korean Med Sci. 2023 Jul 10;38(27):e205. doi: 10.3346/jkms.2023.38.e205.ABSTRACTTixagevimab/cilgavimab is a monoclonal antibody used to prevent coronavirus disease 2019 among immunocompromised hosts and maintained neutralizing activity against early omicron variants. Omicron BN.1 became a dominant circulating strain in Korea early 2023, but its susceptibility to tixagevimab/cilgavimab is unclear. We conducted plaque reduction neutralization test (PRNT) against BN.1 in a prospective cohort (14 patients and 30 specimens). BN.1 PRNT was conducted for one- and three-months after tixagevimab/cilgavimab administration and the ...
Source: Journal of Korean Medical Science - July 11, 2023 Category: Biomedical Science Authors: Jinyoung Yang Seokhwan Hyeon Jin Yang Baek Min Seo Kang Keon Young Lee Young Ho Lee Kyungmin Huh Sun Young Cho Cheol-In Kang Doo Ryeon Chung Kyong Ran Peck Gunho Won Hye Won Lee Kwangwook Kim Insu Hwang So Yeon Lee Byung Chul Kim Yoo-Kyoung Lee Jae-Hoon K Source Type: research
Risk Factors for Sudden Death Within 2 Days After Diagnosis of COVID-19 in Korea
CONCLUSION: To our knowledge, this is the first study on the risk factors for sudden death after a diagnosis of COVID-19, which included age, underlying condition, vaccination status, and place of death. Additionally, individuals aged < 60 years without an underlying condition were at high risk for sudden death. However, this group has relatively low interest in health, as can be seen from the high non-vaccination rate (16.1% of the general population vs. 61.6% of the corresponding group). Therefore, there is a possibility for the presence of an uncontrolled underlying disease in this population. In addition, many sudde...
Source: Journal of Korean Medical Science - July 11, 2023 Category: Biomedical Science Authors: So Young Choi Boyeong Ryu Hyun-Ju Lee Dong-Hwii Kim Eunjeong Shin Seong-Sun Kim Donghyok Kwon Source Type: research
Effectiveness of Paxlovid, an Oral Antiviral Drug, Against the Omicron BA.5 Variant in Korea: Severe Progression and Death Between July and November 2022
CONCLUSION: Paxlovid is effective at reducing the risk of death due to COVID-19 in patients with omicron BA.5 infection, especially in older patients, regardless of vaccination status. This suggests that older patients with COVID-19-related symptoms should be administered Paxlovid, regardless of their vaccination status, to reduce severity and risk of death.PMID:37431541 | PMC:PMC10332951 | DOI:10.3346/jkms.2023.38.e211
Source: Journal of Korean Medical Science - July 11, 2023 Category: Biomedical Science Authors: Jong Mu Kim Min-Gyu Yoo Soon Jong Bae Jungyeon Kim Hyungmin Lee Source Type: research
Loss of Neutralizing Activity of Tixagevimab/Cilgavimab (Evusheld ™) Against Omicron BN.1, a Dominant Circulating Strain Following BA.5 During the Seventh Domestic Outbreak in Korea in Early 2023
J Korean Med Sci. 2023 Jul 10;38(27):e205. doi: 10.3346/jkms.2023.38.e205.ABSTRACTTixagevimab/cilgavimab is a monoclonal antibody used to prevent coronavirus disease 2019 among immunocompromised hosts and maintained neutralizing activity against early omicron variants. Omicron BN.1 became a dominant circulating strain in Korea early 2023, but its susceptibility to tixagevimab/cilgavimab is unclear. We conducted plaque reduction neutralization test (PRNT) against BN.1 in a prospective cohort (14 patients and 30 specimens). BN.1 PRNT was conducted for one- and three-months after tixagevimab/cilgavimab administration and the ...
Source: Journal of Korean Medical Science - July 11, 2023 Category: Biomedical Science Authors: Jinyoung Yang Seokhwan Hyeon Jin Yang Baek Min Seo Kang Keon Young Lee Young Ho Lee Kyungmin Huh Sun Young Cho Cheol-In Kang Doo Ryeon Chung Kyong Ran Peck Gunho Won Hye Won Lee Kwangwook Kim Insu Hwang So Yeon Lee Byung Chul Kim Yoo-Kyoung Lee Jae-Hoon K Source Type: research
Risk Factors for Sudden Death Within 2 Days After Diagnosis of COVID-19 in Korea
CONCLUSION: To our knowledge, this is the first study on the risk factors for sudden death after a diagnosis of COVID-19, which included age, underlying condition, vaccination status, and place of death. Additionally, individuals aged < 60 years without an underlying condition were at high risk for sudden death. However, this group has relatively low interest in health, as can be seen from the high non-vaccination rate (16.1% of the general population vs. 61.6% of the corresponding group). Therefore, there is a possibility for the presence of an uncontrolled underlying disease in this population. In addition, many sudde...
Source: Journal of Korean Medical Science - July 11, 2023 Category: Biomedical Science Authors: So Young Choi Boyeong Ryu Hyun-Ju Lee Dong-Hwii Kim Eunjeong Shin Seong-Sun Kim Donghyok Kwon Source Type: research
Effectiveness of Paxlovid, an Oral Antiviral Drug, Against the Omicron BA.5 Variant in Korea: Severe Progression and Death Between July and November 2022
CONCLUSION: Paxlovid is effective at reducing the risk of death due to COVID-19 in patients with omicron BA.5 infection, especially in older patients, regardless of vaccination status. This suggests that older patients with COVID-19-related symptoms should be administered Paxlovid, regardless of their vaccination status, to reduce severity and risk of death.PMID:37431541 | PMC:PMC10332951 | DOI:10.3346/jkms.2023.38.e211
Source: Journal of Korean Medical Science - July 11, 2023 Category: Biomedical Science Authors: Jong Mu Kim Min-Gyu Yoo Soon Jong Bae Jungyeon Kim Hyungmin Lee Source Type: research
Loss of Neutralizing Activity of Tixagevimab/Cilgavimab (Evusheld ™) Against Omicron BN.1, a Dominant Circulating Strain Following BA.5 During the Seventh Domestic Outbreak in Korea in Early 2023
J Korean Med Sci. 2023 Jul 10;38(27):e205. doi: 10.3346/jkms.2023.38.e205.ABSTRACTTixagevimab/cilgavimab is a monoclonal antibody used to prevent coronavirus disease 2019 among immunocompromised hosts and maintained neutralizing activity against early omicron variants. Omicron BN.1 became a dominant circulating strain in Korea early 2023, but its susceptibility to tixagevimab/cilgavimab is unclear. We conducted plaque reduction neutralization test (PRNT) against BN.1 in a prospective cohort (14 patients and 30 specimens). BN.1 PRNT was conducted for one- and three-months after tixagevimab/cilgavimab administration and the ...
Source: Journal of Korean Medical Science - July 11, 2023 Category: Biomedical Science Authors: Jinyoung Yang Seokhwan Hyeon Jin Yang Baek Min Seo Kang Keon Young Lee Young Ho Lee Kyungmin Huh Sun Young Cho Cheol-In Kang Doo Ryeon Chung Kyong Ran Peck Gunho Won Hye Won Lee Kwangwook Kim Insu Hwang So Yeon Lee Byung Chul Kim Yoo-Kyoung Lee Jae-Hoon K Source Type: research
